Audit: QRS - Royal Jelly for Health & Longevity
Audit conducted on 31/07/2026 03:15 using AI4L / Opus 4.8
Summary
| Items | Count |
|---|---|
| Total | 91 |
| Passed | 82 |
| Failed | 0 |
| N/A | 9 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | All doses, markers, tiers, contraindications, and interactions trace to the ER. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “small and inconsistent”, “single small studies”, “never been tested in people” mirror ER caution. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | “sometimes fatal allergic reactions” preserves ER’s “occasionally fatal”; contraindications kept absolute. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications, interactions, benefits, risks each drawn from matching ER sections. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT IDs, or brand names introduced; none present in QRS. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No new attributions added. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Objective, measured framing consistent with ER. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Data-driven and accessible throughout. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Presents information without prescribing. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No directive advice; facts presented neutrally. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Doses and markers stated as facts, not recommendations. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person address. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Plain language with brief clinical labels only where needed. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Compact cells and lists. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | No “you”/reader address. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Framing suits proactive longevity audience. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Protocol, monitoring, and screening reflect a committed audience. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Not general-population framing. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Weighting reflects proactive audience. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging”. Proper names that contain “anti-aging” are quoted verbatim. | 🟢 | Uses “Longevity”; no “anti-aging” phrasing. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language. Direct quotes from sources are exempt. | 🟢 | Formal terminology; “blood sugar” mirrors ER’s own usage. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: card/section headings (“Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”); gate headings (“Contraindications”, “Key Interactions”); tier labels (“High”, “Medium”, “Low”, “Speculative”); Monitoring column headers (“Marker”, “Target”, “Why”). | 🟢 | All fixed headings and labels present and unmodified. |
| 3.2 | All “…” from the [qrs_template] are present in the QRS. | 🟢 | Full variable set present (header, at_a_glance, actions, times, benefits, gates, risks, markers, cadence, qualitative). |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | No stray modifications. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No relevant ER source section is empty. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Interaction/contraindication labels match ER wording. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Labels faithful to ER. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji indicators; tiers use bold text labels. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Content condensed to fit a single page. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Metadata comment is the first element after doctype (lines 2–14). |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | YAML delimited by — at lines 3 and 13. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in HTML comment; not rendered. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Values trimmed; only “duration” quoted (contains colon). |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | er_filename: royal_jelly_2026-0731-0154_Opus_ER.md |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | qrs_prompt_version: 26.7.02 matches prompt version. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” | 🟢 | qrs_creation_date: 2026-0731-0308. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. | 🟢 | “Opus” is a single word. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | qrs_creator_ai_fullname: Opus 4.8. |
| 5.11 | The full name of the AI consists of the nickname and the model version number and no additional qualifier | 🟢 | “Opus 4.8” — nickname plus version, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | qrs_filename: royal_jelly_2026-0731-0154_Opus_QRS.html. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Frontmatter clean and consistent. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet”. The [canonical_topic] is HTML-entity-encoded as needed. | 🟢 | “Royal Jelly for Health & Longevity - Quick Reference Sheet”. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed. | 🟢 | “Royal Jelly for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | 2026-0731 → 07/31/2026. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | “Opus 4.8”. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header carries only date and model subline. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Distills the Conclusion’s benefit/risk balance. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 57 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Menopause, oxidative stress, metabolic, single-study, longevity, allergy each trace to the ER. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | Uses plain terms (blood sugar, cholesterol, allergic reactions); no acronyms. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial citations. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No statistics or effect sizes. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Drawn from “Populations who should avoid it”. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | Allergy, asthma, anaphylaxis, hormone-sensitive cancers, pregnancy/breastfeeding, children all present. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Each item is an <li>. |
| 8.4 | Items are as concise as possible. No trailing explanations, elaborations, mechanistic rationale, attributions, citations, study details. No content after an em/en/hyphen dash. | 🟢 | Concise; no trailing dash clauses. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved, kept as concise as possible. | 🟢 | “(precautionary)”, “moderate-to-severe”, “(unless medically supervised)” preserved. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>”) that depends on an explanatory phrase, normalize to a plain comma-separated list rather than carrying the bare symbol. | N/A | ER contraindications use no ranking notation. |
| 8.7 | If no [stop_items] are present the section is left empty | N/A | Contraindications are present. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Drawn from the interactions bullets. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Anticoagulants, BP meds, diabetes meds, bee products, BP/blood-sugar supplements listed. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Each item is an <li>. |
| 9.4 | Items are as concise as possible. No trailing explanations, elaborations, mechanistic rationale, attributions, citations, study details. No content after an em/en/hyphen dash. | 🟢 | Concise; no trailing dash clauses. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved, kept concise. | 🟢 | Drug/example classes preserved (warfarin; ACE inhibitors, CCBs; metformin, sulfonylureas, insulin; CoQ10, garlic, omega-3; berberine, cinnamon). |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>”), normalize to a plain comma-separated list rather than carrying the bare symbol. | N/A | ER interactions use no ranking notation. |
| 9.7 | If no [caution_items] are present the section is left empty | N/A | Key interactions are present. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | Dose, timing, formulation from Therapeutic Protocol. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Standard dose, timing, formulation. |
| 10.3 | If less than three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible. | N/A | Three distinct actions are present. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All three action cells populated from the ER. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Menopausal, metabolic/inflammatory, premenstrual — all named in the ER’s time-to-effect bullet. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Menopausal (Medium) first, then metabolic/inflammatory, then premenstrual. |
| 11.3 | If less than three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible. | N/A | Three time-to-effect aspects are present. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All three time cells populated from the ER. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect information. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Tiers mirror ER Medium/Low/Speculative benefits. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four present. |
| 12.3 | Items are as concise as possible. No explanations, elaborations, effect sizes, qualifiers, attributions, citations, study details, mechanistic explanations. | 🟢 | Terse benefit descriptors only. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | “⚠️ Conflicted” and other qualifiers stripped. |
| 12.5 | If no items of a specific sub-section are present the respective is set to “display=none”, not filled with empty-state phrasing. | 🟢 | benefits_high (absent in ER) set to display:none. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | Tiers mirror ER risk headings. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four populated. |
| 13.3 | Items are as concise as possible. No explanations, elaborations, effect sizes, qualifiers, attributions, citations, study details, mechanistic explanations. | 🟢 | Terse risk descriptors only. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | “(Topical Use)”, “(Rare)” stripped. |
| 13.5 | If no items of a specific sub-section are present the respective is set to “display=none”, not filled with empty-state phrasing. | N/A | All four risk tiers contain items. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Markers and cadence drawn from Monitoring Protocol. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All 8 ER biomarkers present with targets and rationale. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Cadence text matches ER (baseline, 8–12 wks, 6–12 mo). |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Drawn from the ER’s qualitative markers list. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All 6 qualitative markers present. |
Issues 31/07/2026 03:15
Pass rate 100.00%. No issues found.